CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Integrative Medicine

Augmentation of light therapy in difficult-to-treat depressed patients: an open-label trial in both unipolar and bipolar patients. 📎

Written by CYBERMED LIFE NEWS
Attachments:
Download this file (Augmentation of light therapy in difficult-to-treat depressed patients - an open-label trial in both unipolar and bipolar patients..pdf)Augmentation of light therapy in difficult-to-treat depressed patients - an open-label trial in both unipolar and bipolar patients..pdf[Augmentation of light therapy in difficult-to-treat depressed patients: an open-label trial in both unipolar and bipolar patients.]665 kB
facebook Share on Facebook
Abstract Title:

Augmentation of light therapy in difficult-to-treat depressed patients: an open-label trial in both unipolar and bipolar patients.

Abstract Source:

Neuropsychiatr Dis Treat. 2015 ;11:2331-8. Epub 2015 Sep 9. PMID: 26396517

Abstract Author(s):

Giovanni Camardese, Beniamino Leone, Riccardo Serrani, Coco Walstra, Marco Di Nicola, Giacomo Della Marca, Pietro Bria, Luigi Janiri

Article Affiliation:

Giovanni Camardese

Abstract:

OBJECTIVES: We investigated the clinical benefits of bright light therapy (BLT) as an adjunct treatment to ongoing psychopharmacotherapy, both in unipolar and bipolar difficult-to-treat depressed (DTD) outpatients.

METHODS: In an open-label study, 31 depressed outpatients (16 unipolar and 15 bipolar) were included to undergo 3 weeks of BLT. Twenty-five completed the treatment and 5-week follow-up.

MAIN OUTCOME MEASURES: Clinical outcomes were evaluated by the Hamilton Depression Rating Scale (HDRS). The Snaith-Hamilton Pleasure Scale and the Depression Retardation Rating Scale were used to assess changes in anhedonia and psychomotor retardation, respectively.

RESULTS: The adjunctive BLT seemed to influence the course of the depressive episode, and a statistically significant reduction in HDRS scores was reported since the first week of therapy. The treatment was well-tolerated, and no patients presented clinical signs of (hypo)manic switch during the overall treatment period. At the end of the study (after 5 weeks from BLT discontinuation), nine patients (36%, eight unipolar and one bipolar) still showed a treatment response. BLT augmentation also led to a significant improvement of psychomotor retardation.

CONCLUSION: BLT combined with the ongoing pharmacological treatment offers a simple approach, and it might be effective in rapidly ameliorating depressive core symptoms of vulnerable DTD outpatients. These preliminary results need to be confirmed in placebo-controlled, randomized, double-blind clinical trial on larger samples.


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.